{"log_id": 605493643594871776, "direction": 0, "words_result_num": 36, "words_result": [{"probability": {"variance": 8.2e-05, "average": 0.993141, "min": 0.970739}, "location": {"width": 226, "top": 139, "height": 34, "left": 93}, "words": "实验室检查和监测"}, {"probability": {"variance": 0.019692, "average": 0.892868, "min": 0.694413}, "location": {"width": 75, "top": 196, "height": 29, "left": 98}, "words": "肾功能"}, {"probability": {"variance": 0.031381, "average": 0.9182, "min": 0.372936}, "location": {"width": 1241, "top": 251, "height": 38, "left": 146}, "words": "本品治疗者中已有血增加和蛋白尿的报告(参见【不反应1建议在开始本品治疗前监测肾"}, {"probability": {"variance": 0.001044, "average": 0.971301, "min": 0.885833}, "location": {"width": 800, "top": 304, "height": 36, "left": 91}, "words": "功能,包括检测血尿素氮(BUN)、尿蛋白和血,并定期复查"}, {"probability": {"variance": 0.015698, "average": 0.950674, "min": 0.476912}, "location": {"width": 1238, "top": 411, "height": 45, "left": 148}, "words": "本品治疗患者中已有高血糖症的报告(参见【不良反应】),建议在开始本品治疗前以及治疗后定期检"}, {"probability": {"variance": 0.011778, "average": 0.945909, "min": 0.507084}, "location": {"width": 1291, "top": 468, "height": 36, "left": 93}, "words": "查空腹血糖。如果本品与可能会引起高血糖的其宫药物联合使用,建议进行更频繁的检查。如果可能,应该"}, {"probability": {"variance": 0.02393, "average": 0.9213, "min": 0.401902}, "location": {"width": 523, "top": 523, "height": 34, "left": 93}, "words": "在老开始本品治疗前获得理想的血控制"}, {"probability": {"variance": 0, "average": 0.955824, "min": 0.955824}, "location": {"width": 59, "top": 578, "height": 34, "left": 93}, "words": "应"}, {"probability": {"variance": 0.019245, "average": 0.9191, "min": 0.435535}, "location": {"width": 1241, "top": 633, "height": 38, "left": 144}, "words": "品治疗患者中曾有血脂异常(包括高胆固血定和高甘油三酯血症)的报、建议在开始本品治疗之"}, {"probability": {"variance": 0.007698, "average": 0.944856, "min": 0.632818}, "location": {"width": 992, "top": 688, "height": 36, "left": 89}, "words": "前检查血胆固醇和甘油二酯,之定期检查,并建议采用适当医学治疗进行处理"}, {"probability": {"variance": 0.088253, "average": 0.78284, "min": 0.362788}, "location": {"width": 139, "top": 742, "height": 34, "left": 93}, "words": "液学"}, {"probability": {"variance": 0.006388, "average": 0.958985, "min": 0.638609}, "location": {"width": 1243, "top": 797, "height": 36, "left": 141}, "words": "本品治疗患老中有血红蛋白、淋巴细胞、中性粒细和血小板减少的报告(参见【不良反应】)。建议"}, {"probability": {"variance": 0.02812, "average": 0.908881, "min": 0.479379}, "location": {"width": 608, "top": 850, "height": 38, "left": 89}, "words": "在开始本品治疗前检查全血细胞计数,并定期复查"}, {"probability": {"variance": 4.7e-05, "average": 0.993836, "min": 0.98094}, "location": {"width": 164, "top": 907, "height": 32, "left": 91}, "words": "药物相互作用"}, {"probability": {"variance": 0.000147, "average": 0.981188, "min": 0.969084}, "location": {"width": 185, "top": 898, "height": 45, "left": 891}, "words": "有限"}, {"probability": {"variance": 0.019101, "average": 0.937438, "min": 0.383222}, "location": {"width": 1238, "top": 962, "height": 36, "left": 144}, "words": "强效CYP3A4排制剂能显著增加依维莫司暴露量,应避免合使用(参见用法用量】和【药物相互作"}, {"probability": {"variance": 0.052832, "average": 0.824453, "min": 0.499439}, "location": {"width": 70, "top": 1017, "height": 29, "left": 91}, "words": "用了)"}, {"probability": {"variance": 0.00973, "average": 0.949401, "min": 0.575511}, "location": {"width": 1206, "top": 1069, "height": 36, "left": 141}, "words": "当合用中效CYP3A4和/或PgP抑制剂时,建议减少本品剂量(参见【用法用量】和【药物相互作用】)"}, {"probability": {"variance": 0.004197, "average": 0.973494, "min": 0.644476}, "location": {"width": 1126, "top": 1126, "height": 34, "left": 144}, "words": "与强效CYP3A4诱导剂合时,建议增加本品剂量(参见【用法用量】和【药物相互作用】"}, {"probability": {"variance": 0.000815, "average": 0.969136, "min": 0.91467}, "location": {"width": 141, "top": 1181, "height": 34, "left": 84}, "words": "肝功能受损"}, {"probability": {"variance": 0.018539, "average": 0.938683, "min": 0.417881}, "location": {"width": 1216, "top": 1236, "height": 36, "left": 139}, "words": "在一项肝功能受损以及肝功能正常受试省参加的研究中评估了共34名受试单次口服品的安全性"}, {"probability": {"variance": 0.015365, "average": 0.904751, "min": 0.475631}, "location": {"width": 1296, "top": 1291, "height": 41, "left": 84}, "words": "耐受性和药代动力学,发现轻度(Chd- Pugh A级)、中度 child-pugh B级)和度( child-pugh C)肝功"}, {"probability": {"variance": 0.018849, "average": 0.922502, "min": 0.457114}, "location": {"width": 738, "top": 1346, "height": 34, "left": 84}, "words": "能受损思者的恢维莫司暴最均增加(参见【药代动力学】"}, {"probability": {"variance": 0.020825, "average": 0.915179, "min": 0.379143}, "location": {"width": 1238, "top": 1401, "height": 36, "left": 139}, "words": "对于重度肝功能受损( childl-pugh C级)的晚肾细胞癌和斯胰腺神经内分泌痛患者,如果预期利益"}, {"probability": {"variance": 0.017713, "average": 0.912427, "min": 0.362881}, "location": {"width": 1259, "top": 1456, "height": 38, "left": 91}, "words": "超过风险,可以减量使用对于轻度(Cid Pugh A级)或中度( Child- Pugh H级)肝功能受损思者"}, {"probability": {"variance": 0.008899, "average": 0.961632, "min": 0.543205}, "location": {"width": 660, "top": 1510, "height": 36, "left": 84}, "words": "建议降低剂量(参见【用法用量】和【药代动力学】)"}, {"probability": {"variance": 0.010282, "average": 0.950927, "min": 0.600252}, "location": {"width": 1238, "top": 1565, "height": 36, "left": 137}, "words": "对于轻度或中度肝功能受损的管膜下巨细电星形细胞瘤患者,应基于治疗药物监测来调本品的剂"}, {"probability": {"variance": 0.019365, "average": 0.933493, "min": 0.370446}, "location": {"width": 1291, "top": 1620, "height": 34, "left": 84}, "words": "量。对于重度肝功能受损的室管膜下巨细胞形细胞痛患者,本品的起始降低大约50%,并基丁治"}, {"probability": {"variance": 0.005165, "average": 0.960883, "min": 0.660951}, "location": {"width": 1019, "top": 1675, "height": 34, "left": 77}, "words": "疗药物监测来调整后续给药(参见【用法用量“治疗药物监测”和“剂量调整”)"}, {"probability": {"variance": 0.000105, "average": 0.988564, "min": 0.973261}, "location": {"width": 114, "top": 1730, "height": 34, "left": 82}, "words": "接种疫苗"}, {"probability": {"variance": 0.02116, "average": 0.936737, "min": 0.360189}, "location": {"width": 1213, "top": 1785, "height": 36, "left": 137}, "words": "在本品治疗期低应避免接种活疫苗,避免与接种过活疫苗的人密切接触。活疫苗举例:内流感、麻疹"}, {"probability": {"variance": 0.022545, "average": 0.89293, "min": 0.390611}, "location": {"width": 900, "top": 1842, "height": 32, "left": 82}, "words": "腺炎、风、口服脊髓灰质炎、卡介面、黄热病、水痘和Y21a伤寒疫苗"}, {"probability": {"variance": 0.008978, "average": 0.957781, "min": 0.493279}, "location": {"width": 1241, "top": 1895, "height": 36, "left": 134}, "words": "对于无需立即治疗的室管膜下巨细胞星形细胞瘤儿童患者,在开始治疗之前应据相应的计划免疫指南"}, {"probability": {"variance": 0.025471, "average": 0.91232, "min": 0.38738}, "location": {"width": 930, "top": 1952, "height": 34, "left": 82}, "words": "完成建议的儿童期活疫苗序列的接种。适当情况下可以采用疫失速接种方案"}, {"probability": {"variance": 0.011114, "average": 0.954327, "min": 0.696178}, "location": {"width": 180, "top": 2004, "height": 34, "left": 80}, "words": "胚胎-胎儿毒性"}, {"probability": {"variance": 0.001667, "average": 0.978014, "min": 0.847368}, "location": {"width": 379, "top": 2061, "height": 32, "left": 132}, "words": "参见【孕妇及哺乳期妇女用药】"}], "language": 3}